Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2023

Panya Aussara, Thepmalee Chutamas, Sawasdee Nunghathai, Saengmuang Sasithorn, Luangwattananun Piriya, Yenchitsomanus Pa-Thai

Abstract excerpt

Precision immunotherapy, driven by genomic and bioinformatic advancements, has emerged as a promising and viable approach to combat cancer. Targeting neoantigens offers the advantage of specific immune responses with minimal off-tumor toxicity. In this study, we investigated the potential of adoptive T cells activated by HLA-restricted neoantigen peptides from driver gene mutations for treating cholangiocarcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cholangiocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A Antigens

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Molecular Docking Simulation

Share to Peptides

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 37939617
DOI: 10.1016/j.biopha.2023.115827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.PMID 37939617Read ↗

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingSemantic proximity Read ↗

Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.Semantic proximity Read ↗

[A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].Semantic proximity Read ↗

Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer.Semantic proximity Read ↗

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.Semantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancerSemantic proximity Read ↗

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read ↗

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cellsSemantic proximity Read ↗

Neoantigens as potential vaccines in hepatocellular carcinomaSemantic proximity Read ↗

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.